CEO Aadhar Poonawalla said in an interview: As the Covid-19 vaccine manufacturing process slows down, the company is using these facilities to manufacture its latest vaccines, which it estimates will increase overall production by two and a half billion. sizes.
The company manufactures AstraZeneca's Covid-19 vaccine, called CoviShield, in India, and also manufactures the protein-based Novavax coronavirus vaccine.
The company invested $2 billion to boost production at the height of the global health crisis.
The company currently sells about 1.5 billion doses of vaccine annually, and total production capacity is estimated at four billion doses.
Poonawalla said the company was in talks with other countries and governments to use the facilities in case of any future outbreaks, but he did not provide further details of the discussions.
He said the Serum Institute has the capacity to produce 100 million doses of anti-malaria drug and can further expand its scope as per the need. It has already produced 25 million doses ahead of its launch in the coming months.
The company is testing a single-dose vaccine against dengue fever, another mosquito-borne, painful and sometimes fatal disease, based on research conducted by the National Institutes of Health in the US.
